Inovio Pharmaceuticals
INO
$12.01
Share price
3.62%
Change (1 day)
1,501.33%
Change (1 year)
Categories
P/S ratio for Inovio Pharmaceuticals (INO)
P/S ratio as of May 2024 (TTM): 374
According to Inovio Pharmaceuticals's latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 373.959. At the end of 2023 the company had a P/S ratio of 167.
P/S ratio history for Inovio Pharmaceuticals from 2001 to 2023
PS ratio at the end of each year
| Year | P/S ratio | Change |
|---|---|---|
| 2023 | 167 | 341.21% |
| 2022 | 37.9 | -93.59% |
| 2021 | 592 | 192.41% |
| 2020 | 202 | 148.69% |
| 2019 | 81.3 | 537.59% |
| 2018 | 12.8 | 44.44% |
| 2017 | 8.83 | -39.22% |
| 2016 | 14.5 | 21.49% |
| 2015 | 12.0 | -77.57% |
| 2014 | 53.3 | 17.75% |
| 2013 | 45.3 | 158.75% |
| 2012 | 17.5 | 214.73% |
| 2011 | 5.56 | -71.71% |
| 2010 | 19.7 | 53.06% |
| 2009 | 12.8 | 17.71% |
| 2008 | 10.9 | 30.14% |
| 2007 | 8.38 | -75.2% |
| 2006 | 33.8 | 176.32% |
| 2005 | 12.2 | -80.32% |
| 2004 | 62.2 | -93.71% |
| 2003 | 988 | 1227.56% |
| 2002 | 74.5 | 2126.05% |
| 2001 | 3.34 |
P/S ratio for similar companies or competitors
| Company | P/S ratio | P/S ratio differencediff. | Country |
|---|---|---|---|
 Johnson & Johnson JNJ | 3.88 | -98.96% | 🇺🇸 USA |
 Novartis NVS | 3.98 | -98.94% | 🇨🇭 Switzerland |
 Pfizer PFE | 2.68 | -99.28% | 🇺🇸 USA |
 Gilead Sciences GILD | 3.00 | -99.20% | 🇺🇸 USA |
 Merck MRK | 5.40 | -98.55% | 🇺🇸 USA |
 GlaxoSmithKline GSK | 2.34 | -99.38% | 🇬🇧 UK |
 Cleveland BioLabs
CBLI | N/A | N/A | 🇺🇸 USA |
 Arrowhead Pharmaceuticals
ARWR | 16.5 | -95.60% | 🇺🇸 USA |